Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Wike

Pain Medicine Knoxville, TN Medical Doctor

NPI 1003884073 CMS profile 932832

501 20Th St, Suite 606, Knoxville, TN 37916

Open in the dashboard

General payments

$1,570

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Wike of Knoxville, TN is reported in the CMS Open Payments database as having received $1,570 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $394 33
2024 General $410 37
2023 General $238 5
2022 General $135 6
2021 General $283 9
2020 General $27 2
2019 General $84 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Wike
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to James Wike were reported at $394. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year James Wike Pain Medicine median Middle half National median
2019 $84 $498 $126–$1,682 $163
2020 $27 $284 $80–$910 $114
2021 $283 $399 $112–$1,219 $132
2022 $135 $455 $137–$1,484 $149
2023 $238 $484 $128–$1,495 $160
2024 $410 $498 $131–$1,540 $164
2025 $394 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $690 67 payments
  2. Stryker Corporation $357 2 payments
  3. Medtronic, Inc. $257 16 payments
  4. Abbott Laboratories $85 5 payments
  5. Nevro Corp. $69 3 payments
  6. Medtronic USA, Inc. $47 1 payment
  7. Smoky Mountain Surgical LLC $36 1 payment
  8. BIOTRONIK NRO, Inc. $29 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,570 96 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $522 53 payments
  2. EVEREST SPINAL SYSTEM $318 2 payments
  3. INTELLIS ADAPTIVESTIM $257 16 payments
  4. OPERON $198 1 payment
  5. VISUM $198 1 payment
  6. OZARK CERVICAL PLATE SYSTEM $159 1 payment
  7. CAPRI CORPECTOMY CAGE SYSTEM $159 1 payment
  8. YUKON OCT SPINAL SYSTEM $159 1 payment
  9. GENERAL PAIN MANAGEMENT $117 10 payments
  10. Omnia $49 2 payments
  11. Other $231 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

28

Median for Pain Management: 951

Drug cost

$211

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 28 $211

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$274,802

Of which drugs: $5,136

Medicare patients

481

Average age 74

Services billed

28,261

271 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 35%
Ischemic heart disease 30%
Diabetes 29%
Chronic kidney disease 27%
COPD 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 144 18,440 $1,864
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 215 2,432 $1,819
Injection, methylprednisolone acetate, 40 mg J1030 Office 87 176 $772
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 150 3,832 $326
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 268 485 $130
Injection, propofol, 10 mg J2704 Office 100 1,186 $95
Injection, fentanyl citrate, 0.1 mg J3010 Office 87 126 $89
Injection, midazolam hydrochloride, per 1 mg J2250 Office 78 148 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record